AXIM Biotechnologies, Inc. (AXIM)
OTCMKTS: AXIM · Delayed Price · USD
-0.0003 (-3.18%)
May 24, 2024, 3:09 PM EDT - Market closed

Company Description

AXIM Biotechnologies, Inc. engages in the development and sale of diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases.

The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests.

It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring.

The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014.

AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.

AXIM Biotechnologies, Inc.
Country Canada
Founded 2010
Industry Biotechnology
Sector Healthcare
Employees 6
CEO John W. Huemoeller II

Contact Details

6191 Cornerstone Court, E, Suite 114
San Diego, California 92121
United States
Phone (212) 751-0001

Stock Details

Ticker Symbol AXIM
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001514946
CUSIP Number 05463V100
ISIN Number US05463V1008
Employer ID 27-4092986
SIC Code 2834

Key Executives

Name Position
John W. Huemoeller II President, Chief Executive Officer and Director
Robert T. Malasek Chief Financial Officer and Secretary
Catalina Valencia J.D. Co-Founder and Chief Executive Officer of Sapphire Biotech, Inc.
Kurt Phinney Chief Operating Officer
Dr. Sergei A. Svarovsky M.B.A., Ph.D. Chief Scientific Officer and Co-Founder of Sapphire Biotech, Inc.
Dr. Alim Seit-Nebi Ph.D. Chief Technology Officer and Co-Founder of Sapphire Biotech, Inc.
Jeffrey A. Busby Senior Vice President of Business Development
Dr. Joseph Tauber M.D. Chief Medical Officer and Chairman of the Medical Advisory Board

Latest SEC Filings

Date Type Title
May 22, 2024 10-Q/A [Amend] Quarterly report
May 20, 2024 10-Q Quarterly Report
May 15, 2024 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Apr 16, 2024 10-K Annual Report
Apr 1, 2024 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Mar 21, 2024 8-K Current Report
Feb 13, 2024 8-K Current Report
Dec 28, 2023 8-K Current Report
Nov 20, 2023 10-Q Quarterly Report
Nov 14, 2023 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB